Bluebird Bio Inc. (Nasdaq: BLUE) reported positive preliminary results for its gene therapy treatment LentiGlobin sending the stock price surging $8.37 to close at $34.46.
Bluebird Bio reports upbeat results
June 16, 2014 at 17:08 PM EDT
Bluebird Bio reports upbeat resultsJune 16, 2014 at 17:08 PM EDT
Bluebird Bio Inc. (Nasdaq: BLUE) reported positive preliminary results for its gene therapy treatment LentiGlobin sending the stock price surging $8.37 to close at $34.46. Related Stocks:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|